Skip to content
Screener

McKesson MCK Q4 2026 Annual earnings

Reported May 7, 2026 · After market close

Revenue$96.3BMiss by $5.1B
EPS$11.69Beat by $0.13
Revenue estimate$101.35B
EPS estimate$11.56
“McKesson's fourth quarter results reflect the strength of our diversified portfolio and disciplined execution against our strategic priorities. Our Fiscal 2026 performance, headlined by 12% revenue growth and 18% adjusted EPS growth, exceeded our long-range growth targets and demonstrates our ability to consistently deliver growth and operating leverage across the enterprise, We delivered significant progress - expanding specialty provider support, accelerating patient access through our scaled and integrated biopharma support services, and continuing to optimize our portfolio through the divestiture of Europe and the planned separation of our Medical-Surgical business. These accomplishments are a direct result of the talent and operational excellence of our employees, and I want to thank Team McKesson for their continued dedication throughout the year.
Brian Tyler

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$109.91B
EPS estimate$10.72

Financials

Q4 2026

Income statement

See full
Revenue$96.3B+6.0%
Gross profit$4.0B+11.1%
Operating income$2.2B+35.1%
Net income$1.7B+33.5%
EPS (diluted)$13.65+37.6%

Balance sheet

See full
Cash & equivalents$4.1B-31.7%
Total debt$10.0B+13.9%
Total equity-$2.2B-4.7%
Total assets$82.3B+9.6%

Cash flow

See full
Operating cash flow$3.4B-55.8%
CapEx$111.0M-34.3%
Free cash flow$3.3B-56.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$106B+25.7%
Enterprise value$111.97B+28.4%
P/E22.3×-3.3×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%-0.1pp
Operating margin1.5%+0.3pp
Net margin1.2%+0.3pp
FCF margin1.4%-0.1pp

Returns & leverage

See full
Current ratio0.9×0.0×

Segments

By segment

See full
North American Pharmaceutical$79.1B—
Oncology & Multispecialty$12.7B—
Medical-Surgical Solutions$2.9B+0.5%
Prescription Technology Solutions$1.5B—

FAQ

When did McKesson report Q4 2026 earnings?
McKesson (MCK) reported Q4 2026 earnings on May 7, 2026 after market close.
What were McKesson's Q4 2026 revenue and EPS?
McKesson reported revenue of $96.3B and eps of $11.69 for Q4 2026.
Did McKesson beat estimates in Q4 2026?
Revenue missed the consensus estimate of $101.35B by $5.1B. EPS beat the consensus estimate of $11.56 by $0.13.
How did McKesson's Q4 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.0% from $90.8B a year earlier and eps grew 15.5% from $10.12.
Where can I find McKesson's Q4 2026 SEC filings?
You can read the 8-K earnings release (0000927653-26-000066) and the 10-K periodic report (0000927653-26-000069) directly on SEC EDGAR. The filing index links above go to sec.gov.